Care Path for the Management of Ulcerative Colitis (CONSTRUCT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01882426|
Recruitment Status : Terminated
First Posted : June 20, 2013
Last Update Posted : May 13, 2016
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis||Other: Enhanced treatment algorithm Other: Usual Care||Phase 4|
Step-care based on symptomatic response remains the overwhelming algorithm of choice in clinical practice. Many subjects receive infliximab only as a last resort, when the subject is very ill and has failed repeated attempts of corticosteroid induction therapy. Although this situation is far from ideal, to change such entrenched physician behavior will require compelling evidence that Step-care results in inferior outcomes to earlier introduction of effective therapy.
Based on these considerations, we will perform a cluster randomization trial in which 40 gastroenterology practices will be randomly assigned to a treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal or a conventional Step-care approach.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||192 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Cluster Randomized Controlled Trial of a Care-Path for the Management of Ulcerative Colitis|
|Study Start Date :||May 2014|
|Actual Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||May 2016|
Active Comparator: Enhanced treatment algorithm
Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
Other: Enhanced treatment algorithm
Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
Placebo Comparator: Usual Care
These subjects will be managed according to local treatment guidelines for the treatment of UC.
Other: Usual Care
usual step care practice
- Proportion of patients in remission at the end of 12 months. [ Time Frame: 12 months ]Remission is defined as 1) a Mayo Clinic Score of ≤2 with rectal bleeding and stool frequency sub-scale scores of 0) with no use of corticosteroids, and 3) normalization of the subject's index inflammatory marker (c-reactive protein or calprotectin). The primary endpoint will be assessed at Month 12.
- Proportion of patients in remission over the course of the study [ Time Frame: 18 months ]The time in remission over the course of the study; occurrence of surgery or hospitalization for Ulcerative Colitis; occurrence of disease-related complications; health related QoL (Short-Form 36 questionnaire [SF-36] and EuroQoL instrument [EQ-5D]); and, subject
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01882426
|Principal Investigator:||Brian G Feagan, MD||Robarts Clinical Trials Inc.|